What’s new, what’s next and where to find us. This is your hub for our CRO lab announcements, insights and events—because in bioanalysis, momentum matters.
Veloxity Labs, a leading bioanalytical CRO specializing in LC-MS bioanalysis, today announced strong first quarter growth and continued expansion in 2026.
Our CEO, Shane Needham, PhD, was recently featured in The Analytical Scientist discussing the impact of GLP-1 receptor agonists and emerging peptide therapeutics.
Veloxity Labs has acquired the SCIEX ZenoTOF 8600 system, becoming the first bioanalytical CRO to bring this accurate-mass system online. The 8600 adds HRAM selectivity/sensitivity and expanded mass range for intact peptides/proteins—speeding method cycles for GLP-1 RAs and broader peptide programs while complementing our triple-quads. Delivery is expected this year; install/qualification begins January 2026.
Read the full release.
We’ve partnered with Carolina Martinez — a record-setting sprinter, Bradley University standout and cancer survivor — in a powerful new NIL collaboration.
We’re proud to support Silo Pharma in advancing SPC-15, a novel intranasal therapy for PTSD. We're providing GLP bioanalysis for their IND-enabling safety study.
Veloxity Labs is proud to participate in the 2026 St. Jude Metamora to Peoria Run, continuing a tradition that reflects our commitment to improving lives.
Veloxity Labs will attend the PBSS Boston IND Filing and Nonclinical Considerations for Emerging Modalities on September 9 in Cambridge, Massachusetts.
Veloxity Labs is a proud sponsor of the 2026 Animal Health Summit one of the leading global gatherings focused on innovation across the animal health industry.
